Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747093 | 0.89 | TNKS (0.45) | KDM4EMAPTTHRBCCR5DPP4 | |
| SCHEMBL3391724 | 0.88 | KDM4E (0.44) | KDM4EMAPTTHRBCCR5DPP4 | |
| SCHEMBL3392414 | 0.87 | MAPT (0.46) | KDM4EMAPTTHRBCCR5DPP4 | |
| SCHEMBL3392338 | 0.86 | PIK3CA (0.44) | KDM4EMAPTTHRBCCR5DPP4 | |
| SCHEMBL4667693 | 0.84 | CCR5 (0.51) | KDM4EMAPTTHRBHRH3CCR5 | |
| SCHEMBL4605335 | 0.83 | CHRM2 (0.46) | HSD11B1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4234708 | 0.82 | DRD2 (0.52) | CCR5HSD11B1CHRM2CHRM4CHRM5 | |
| SCHEMBL3390308 | 0.82 | KDM4E (0.45) | KDM4EMAPTTHRBCCR5DPP4 | |
| SCHEMBL20599032 | 0.82 | CCR5 (0.49) | KDM4EMAPTTHRBCCR5DPP4 | |
| SCHEMBL4645974 | 0.80 | CHRM1 (0.59) | KDM4EMAPTTHRBCCR5HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481566-B2 | 4-Fluoro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; for treatment of psychotic disorders and cognitive impairment | GLAXO GROUP LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8481566-B2 | 4-Fluoro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; for treatment of psychotic disorders and cognitive impairment | GLAXO GROUP LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8481566-B2 | 4-Fluoro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; for treatment of psychotic disorders and cognitive impairment | GLAXO GROUP LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8283364-B2 | Psyvhological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8283364-B2 | Psyvhological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8283364-B2 | Psyvhological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| EP-1943230-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2010-12-22 | — | — | EP | disclosed |
| EP-1943230-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1943230-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| WO-2007036715-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036715-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | KDM4E 4355/4885MAPT 2089/4885THRB 331/4885 |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | CHRM1, CHRM2, CHRM5 | KDM4E 4204/4885MAPT 1695/4885THRB 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.